Floatz logo

Durvalumab

Head and Neck Carcinoma

AstraZenecamonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Head and Neck Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Pembrolizumab
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Tadalafil
University of California, San Diego
Phase 2B
Binimetinib
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →